The Sensitivity of Massively Parallel Sequencing for Detecting Candidate Infectious Agents Associated with Human Tissue

Massively parallel sequencing technology now provides the opportunity to sample the transcriptome of a given tissue comprehensively. Transcripts at only a few copies per cell are readily detectable, allowing the discovery of low abundance viral and bacterial transcripts in human tissue samples. Here we describe an approach for mining large sequence data sets for the presence of microbial sequences. Further, we demonstrate the sensitivity of this approach by sequencing human RNA-seq libraries spiked with decreasing amounts of an RNA-virus. At a modest depth of sequencing, viral transcripts can be detected at frequencies less than 1 in 1,000,000. With current sequencing platforms approaching outputs of one billion reads per run, this is a highly sensitive method for detecting putative infectious agents associated with human tissues

Assessing the Diversity and Specificity of Two Freshwater Viral Communities through Metagenomics

Transitions between saline and fresh waters have been shown to be infrequent for microorganisms. Based on host-specific interactions, the presence of specific clades among hosts suggests the existence of freshwater-specific viral clades. Yet, little is known about the composition and diversity of the temperate freshwater viral communities, and even if freshwater lakes and marine waters harbor distinct clades for particular viral sub-families, this distinction remains to be demonstrated on a community scale

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Proper Timing of Foot-and-Mouth Disease Vaccination of Piglets with Maternally Derived Antibodies Will Maximize Expected Protection Levels

We investigated to what extent maternally derived antibodies interfere with foot-and-mouth disease (FMD) vaccination in order to determine the factors that influence the correct vaccination for piglets. Groups of piglets with maternally derived antibodies were vaccinated at different time points following birth, and the antibody titers to FMD virus (FMDV) were measured using virus neutralization tests (VNT). We used 50 piglets from 5 sows that had been vaccinated 3 times intramuscularly in the neck during pregnancy with FMD vaccine containing strains of FMDV serotypes O, A, and Asia-1. Four groups of 10 piglets were vaccinated intramuscularly in the neck at 3, 5, 7, or 9 weeks of age using a monovalent Cedivac-FMD vaccine (serotype A TUR/14/98). One group of 10 piglets with maternally derived antibodies was not vaccinated, and another group of 10 piglets without maternally derived antibodies was vaccinated at 3 weeks of age and served as a control group. Sera samples were collected, and antibody titers were determined using VNT. In our study, the antibody responses of piglets with maternally derived antibodies vaccinated at 7 or 9 weeks of age were similar to the responses of piglets without maternally derived antibodies vaccinated at 3 weeks of age. The maternally derived antibody levels in piglets depended very strongly on the antibody titer in the sow, so the optimal time for vaccination of piglets will depend on the vaccination scheme and quality of vaccine used in the sows and should, therefore, be monitored and reviewed on regular basis in countries that use FMD prophylactic vaccination

Macromolecular Design Strategies for Preventing Active‐Material Crossover in Non‐Aqueous All‐Organic Redox‐Flow Batteries

Intermittent energy sources, including solar and wind, require scalable, low‐cost, multi‐hour energy storage solutions in order to be effectively incorporated into the grid. All‐Organic non‐aqueous redox‐flow batteries offer a solution, but suffer from rapid capacity fade and low Coulombic efficiency due to the high permeability of redox‐active species across the battery’s membrane. Here we show that active‐species crossover is arrested by scaling the membrane’s pore size to molecular dimensions and in turn increasing the size of the active material above the membrane’s pore‐size exclusion limit. When oligomeric redox‐active organics (RAOs) were paired with microporous polymer membranes, the rate of active‐material crossover was reduced more than 9000‐fold compared to traditional separators at minimal cost to ionic conductivity. This corresponds to an absolute rate of RAO crossover of less than 3 μmol cm−2 day−1 (for a 1.0 m concentration gradient), which exceeds performance targets recently set forth by the battery industry. This strategy was generalizable to both high and low‐potential RAOs in a variety of non‐aqueous electrolytes, highlighting the versatility of macromolecular design in implementing next‐generation redox‐flow batteries.Better sieving through chemistry: Macromolecular chemistry provides a general approach for blocking redox‐active organic molecules from crossing through battery membranes at minimal cost to ionic conductivity. This advance solves a critical challenge facing next‐generation redox‐flow batteries, clearing the way toward efficient, low‐cost grid‐scale energy storage.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/136045/1/anie201610582-sup-0001-misc_information.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/136045/2/anie201610582_am.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/136045/3/anie201610582.pd

Macromolecular Design Strategies for Preventing Active‐Material Crossover in Non‐Aqueous All‐Organic Redox‐Flow Batteries

Intermittent energy sources, including solar and wind, require scalable, low‐cost, multi‐hour energy storage solutions in order to be effectively incorporated into the grid. All‐Organic non‐aqueous redox‐flow batteries offer a solution, but suffer from rapid capacity fade and low Coulombic efficiency due to the high permeability of redox‐active species across the battery’s membrane. Here we show that active‐species crossover is arrested by scaling the membrane’s pore size to molecular dimensions and in turn increasing the size of the active material above the membrane’s pore‐size exclusion limit. When oligomeric redox‐active organics (RAOs) were paired with microporous polymer membranes, the rate of active‐material crossover was reduced more than 9000‐fold compared to traditional separators at minimal cost to ionic conductivity. This corresponds to an absolute rate of RAO crossover of less than 3 μmol cm−2 day−1 (for a 1.0 m concentration gradient), which exceeds performance targets recently set forth by the battery industry. This strategy was generalizable to both high and low‐potential RAOs in a variety of non‐aqueous electrolytes, highlighting the versatility of macromolecular design in implementing next‐generation redox‐flow batteries.Besseres Sieben durch Chemie: Makromolekulare Chemie bietet einen allgemeinen Ansatz, um bei nur minimalem Verlust an Ionenleitfähigkeit den Durchtritt redoxaktiver organischer Moleküle durch Batteriemembranen zu blockieren. Dieses Resultat löst ein zentrales Problem für die Entwicklung von Redox‐Flow‐Batterien der nächsten Generation und bereitet den Weg für eine effiziente und preisgünstige Energiespeicherung.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/135975/1/ange201610582-sup-0001-misc_information.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/135975/2/ange201610582_am.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/135975/3/ange201610582.pd

Macromolecular Design Strategies for Preventing Active‐Material Crossover in Non‐Aqueous All‐Organic Redox‐Flow Batteries

Intermittent energy sources, including solar and wind, require scalable, low‐cost, multi‐hour energy storage solutions in order to be effectively incorporated into the grid. All‐Organic non‐aqueous redox‐flow batteries offer a solution, but suffer from rapid capacity fade and low Coulombic efficiency due to the high permeability of redox‐active species across the battery’s membrane. Here we show that active‐species crossover is arrested by scaling the membrane’s pore size to molecular dimensions and in turn increasing the size of the active material above the membrane’s pore‐size exclusion limit. When oligomeric redox‐active organics (RAOs) were paired with microporous polymer membranes, the rate of active‐material crossover was reduced more than 9000‐fold compared to traditional separators at minimal cost to ionic conductivity. This corresponds to an absolute rate of RAO crossover of less than 3 μmol cm−2 day−1 (for a 1.0 m concentration gradient), which exceeds performance targets recently set forth by the battery industry. This strategy was generalizable to both high and low‐potential RAOs in a variety of non‐aqueous electrolytes, highlighting the versatility of macromolecular design in implementing next‐generation redox‐flow batteries.Besseres Sieben durch Chemie: Makromolekulare Chemie bietet einen allgemeinen Ansatz, um bei nur minimalem Verlust an Ionenleitfähigkeit den Durchtritt redoxaktiver organischer Moleküle durch Batteriemembranen zu blockieren. Dieses Resultat löst ein zentrales Problem für die Entwicklung von Redox‐Flow‐Batterien der nächsten Generation und bereitet den Weg für eine effiziente und preisgünstige Energiespeicherung.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/135975/1/ange201610582-sup-0001-misc_information.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/135975/2/ange201610582_am.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/135975/3/ange201610582.pd

Macromolecular Design Strategies for Preventing Active-Material Crossover in Non-Aqueous All-Organic Redox-Flow Batteries.

Intermittent energy sources, including solar and wind, require scalable, low-cost, multi-hour energy storage solutions in order to be effectively incorporated into the grid. All-Organic non-aqueous redox-flow batteries offer a solution, but suffer from rapid capacity fade and low Coulombic efficiency due to the high permeability of redox-active species across the battery's membrane. Here we show that active-species crossover is arrested by scaling the membrane's pore size to molecular dimensions and in turn increasing the size of the active material above the membrane's pore-size exclusion limit. When oligomeric redox-active organics (RAOs) were paired with microporous polymer membranes, the rate of active-material crossover was reduced more than 9000-fold compared to traditional separators at minimal cost to ionic conductivity. This corresponds to an absolute rate of RAO crossover of less than 3 μmol cm-2  day-1 (for a 1.0 m concentration gradient), which exceeds performance targets recently set forth by the battery industry. This strategy was generalizable to both high and low-potential RAOs in a variety of non-aqueous electrolytes, highlighting the versatility of macromolecular design in implementing next-generation redox-flow batteries

Macromolecular Design Strategies for Preventing Active-Material Crossover in Non-Aqueous All-Organic Redox-Flow Batteries.

Intermittent energy sources, including solar and wind, require scalable, low-cost, multi-hour energy storage solutions in order to be effectively incorporated into the grid. All-Organic non-aqueous redox-flow batteries offer a solution, but suffer from rapid capacity fade and low Coulombic efficiency due to the high permeability of redox-active species across the battery's membrane. Here we show that active-species crossover is arrested by scaling the membrane's pore size to molecular dimensions and in turn increasing the size of the active material above the membrane's pore-size exclusion limit. When oligomeric redox-active organics (RAOs) were paired with microporous polymer membranes, the rate of active-material crossover was reduced more than 9000-fold compared to traditional separators at minimal cost to ionic conductivity. This corresponds to an absolute rate of RAO crossover of less than 3 μmol cm-2  day-1 (for a 1.0 m concentration gradient), which exceeds performance targets recently set forth by the battery industry. This strategy was generalizable to both high and low-potential RAOs in a variety of non-aqueous electrolytes, highlighting the versatility of macromolecular design in implementing next-generation redox-flow batteries